MENU
APR 23, 2020 10:30 AM PDT

Keynote Presentation: Systematic identification of therapeutic strategies that leverage tumor evolution

Speaker

Abstract

Our laboratory uses tools from pharmacology, genomics, and cell signaling to identify new precision anticancer therapeutic strategies. Under this broad heading, our work involves three key areas of emphasis. First, we use custom functional and structural genomic tools to define the landscape of signaling pathways capable of driving resistance to therapy (for example, Science Signaling 2012, 5, rs4; Science Signaling 2014, 7, ra121; and Cell Reports 2017, 20, 999). Second, we utilize knowledge of resistance landscapes to identify new therapeutic strategies that have the potential to circumvent resistance evolution (for example, Science Signaling 2014, 7, ra122; Nature Communications 2017, 8, 15617; Cell Reports 2017, 21, 2796; Nature Communications 2018, 9, 4274; Science Advances 2019, 5, eaaw9162; and Nature Genetics 2020, 52, 408). Finally, we use unbiased approaches to define mechanism-based, targetable vulnerabilities in human cancers for application to malignancies characterized by “undruggable” genetic drivers or immunologically “cold” microenvironments, where in many cases these vulnerabilities center on the dysregulated structure and function of tumor mitochondria (for example, Science Translational Medicine 2016, 8, ra175; Nature Communications 2018, 9, 1677; Nature Communications 2018, 9, 3513; and Cell Metabolism 2019, 29, 1217). Collectively, these studies are leading to both fundamental new insights into the core survival circuitry operating in defined human tumor subsets as well as novel translational therapeutics. In this talk, I will provide an overview of our work, with a particular focus on studies that have identified mechanisms of convergent tumor evolution and associated strategies to leverage this phenomenon to build combination therapies that select against resistance.

Learning Objectives:
1. Understand strategies for designing mechanism-based combination therapies to overcome resistance

2. Learn examples of convergent resistance evolution

3. Use functional genomics and pharmacological screening to identify therapeutic targets


Show Resources
You May Also Like
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
JUN 21, 2022 6:00 AM PDT
JUN 21, 2022 6:00 AM PDT
Date: June 21, 2022 Time: 6:00am (PDT), 9:00am (EDT), 3:00pm (CEST) The global understanding and practice of medicine is currently undergoing a revolutionary change. This shift to precision...
JUN 28, 2022 7:00 AM PDT
JUN 28, 2022 7:00 AM PDT
Date: June 28, 2022 Time: 3:00pm (BST), 4:00pm (CET), 9:00am (CST), 7am (PST) Light-sheet microscopy is an extremely versatile imaging technique with a vast range of implementations that are...
AUG 16, 2022 11:00 AM PDT
AUG 16, 2022 11:00 AM PDT
Date: August 16, 2022 Time: 11:00am (PDT), 2:00pm (EDT), 8:00pm (CEST) Understanding genomic variation in the context of cancer is paramount to identifying disease drivers and informing pers...
OCT 11, 2022 8:00 AM PDT
C.E. CREDITS
OCT 11, 2022 8:00 AM PDT
Date: October 11, 2022 Time: 8:00am (PDT), 11:00pm (EDT), 5:00pm (CEST) Multiomic profiling of cell populations at single-cell resolution is revolutionizing scientists’ understanding o...
APR 26, 2022 7:00 AM PDT
C.E. CREDITS
APR 26, 2022 7:00 AM PDT
Date: April 19, 2022 Time: 7:00am (PDT), 10:00am (EDT), 4:00pm (CEST) High-content (HC) phenotypic profiling approaches are a powerful tool to study the effect of biological, genetic, and ch...
Loading Comments...
Show Resources